Vaccines work by controlled exposure to harmless whole-pathogens (virus or bacteria) or specific antigens, which ensures that the immune system can adequately neutralize the pathogen when the organism is confronted with it.
Conventional vaccinations comprise conjugate and subunit vaccines, as well as live-attenuated, inactivated, and replication-defective pathogens. They may contain live-attenuated organisms; inactivated organisms; inactivated toxins; antigens or antigenic epitopes, like subunit and conjugate vaccines.
Limitations of traditional technologies have triggered the application of novel vaccine approaches, including nucleic acid vaccines, like DNA vaccines and mRNA vaccines, viral vector vaccines, as well as microbial vector vaccines encoding the target antigens or antigenic epitopes.
Yaohai Bio-Pharma offers a range of vaccine services using microbial fermentation systems, as follows:
Technical route | Business | Deliverables (intermediate/drug substance/drug product) | Services |
mRNA vaccines | Yes | DS or DP: mRNA or LNP-mRNAOur partner, NanoStar, licensed their own LNP patents to us. | Vaccines CRDMO services, including intermediates, drug substances (DS) or drug products (DP) 【GMP grade】 • Research samples preparation, such as mRNA, DNA or proteins; • Microbial cell banking; • Process development, such as fermentation, purification and formulation; • Analysis method development; • GMP manufacture of mRNA, DNA, proteins, live bacteria (BSL-1/BSL-2 Laboratory); • Quality control of the products; • Registration. |
DNA vaccines | Yes | DS or DP: Plasmid DNA | |
Viral vector vaccines | Yes | Intermediate: Plasmid DNA | |
Subunit vaccines | Yes | DS or DP (adjuvant): recombinant antigens-based vaccinese.g., Prophylactic vaccines for HPV, RSV, or therapeutic vaccines for cancer, hypertension. | |
Protein/peptide-based therapeutic vaccines | Yes | ||
Conjugate vaccines | Yes | DS or DP: Conjugate vaccinese.g., Pneumococcal, meningococcal vaccines.Intermediate: Carrier proteinse.g., VLP, CRM197, tetanus toxin, etc. | |
Polysaccharide vaccine | Yes | DS or DP (adjuvant): Polysaccharide vaccinee.g., Typhim Vi vaccine, pneumococcal vaccine. | |
Toxoid vaccines | Yes | DS or DP: Inactivated toxoide.g., Diphtheria, tetanus and pertussis toxin, etc. | |
Live, attenuated vaccines (microbial) | Yes | DS or DP: Live, attenuated vaccinese.g., BCG live, cholera vaccine live. | |
Inactivated vaccines (microbial) | Yes | DS or DP: Inactivated vaccinese.g., human typhoid Salmonella Inactivated vaccine | |
Microbial-vector vaccines | Yes | DS or DP: Live microbial products |
Different types of vaccines are produced using different processes. Click here to find more details of our vaccine solutions.
Gebre MS, Brito LA, Tostanoski LH, Edwards DK, Carfi A, Barouch DH. Novel approaches for vaccine development. Cell. 2021 Mar 18;184(6):1589-1603. doi: 10.1016/j.cell.2021.02.030.